SCHEMBL382928

SCHEMBL382928

COC1O[C@H](C(C)OC(=O)c2ccc([N+](=O)[O-])cc2)[C@@H](O)[C@H]1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
ADRB2 P07550 2/20 0.40
ADRB1 P08588 2/20 0.40
ADRB3 P13945 2/20 0.40
EPHX1 P07099 1/20 0.40
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
HTT P42858 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2813727 1.00 POLB (0.42) POLBL3MBTL1KMT2AMEN1ADRB2
SCHEMBL780312 1.00 POLB (0.42) POLBL3MBTL1KMT2AMEN1ADRB2
SCHEMBL384073 0.83 TSHR (0.41) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL781561 0.83 TSHR (0.41) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL2814026 0.83 TSHR (0.41) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL780151 0.82 ALDH1A1 (0.48) POLBL3MBTL1KMT2AMEN1ADRB2
SCHEMBL384063 0.82 ALDH1A1 (0.48) POLBL3MBTL1KMT2AMEN1ADRB2
SCHEMBL779104 0.81 LGALS3 (0.44) POLBL3MBTL1KMT2AMEN1EPHX1
SCHEMBL383198 0.81 LGALS3 (0.44) POLBL3MBTL1KMT2AMEN1EPHX1
SCHEMBL14643936 0.74 ALDH1A1 (0.42) POLBL3MBTL1KMT2AMEN1ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2623104-A1 Substituted nucleoside and nucleotide analogs Alios Biopharma, Inc. (US) 2013-08-07 EP disclosed
EP-2408306-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS Alios Biopharma, Inc. (US) 2012-01-25 EP disclosed
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-30 US disclosed
WO-2010108140-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249068-A1 SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS PNP, TYMP, NTPCR POLB 135/4885L3MBTL1 963/4885KMT2A 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.